Cargando…

Panic Disorder and Chronic Caffeine Use: A Case-control Study

BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemograph...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Veruska Andrea, Hoirisch-Clapauch, Silvia, Nardi, Antonio E., Freire, Rafael Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882139/
https://www.ncbi.nlm.nih.gov/pubmed/31819760
http://dx.doi.org/10.2174/1745017901915010120
_version_ 1783474089492480000
author Santos, Veruska Andrea
Hoirisch-Clapauch, Silvia
Nardi, Antonio E.
Freire, Rafael Christophe
author_facet Santos, Veruska Andrea
Hoirisch-Clapauch, Silvia
Nardi, Antonio E.
Freire, Rafael Christophe
author_sort Santos, Veruska Andrea
collection PubMed
description BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemographic or clinical features. METHODS: 65 adults with PD and 66 healthy controls were included in the current study. Their caffeine intake within the previous week was quantified with a questionnaire and compared. Harmful caffeine use was defined as consumption above 400 mg/day of caffeine. We tested for correlations between caffeine intake, demographic and clinical features. RESULTS: Patients consumed significantly more caffeine than controls (P < 0.001). 14% (N = 9) of the PD patients made harmful use of caffeine. The use of caffeine-containing medications was observed in 40% (N = 26) of the PD patients and 6% (N = 4) of controls. Consumption of energy drinks was observed in 11% (N = 7) of PD patients and in none of the healthy subjects. Patients reported sleeping significantly less than controls (P < 0.001). In PD patients, caffeine consumption was not correlated with the presence of panic attacks or comorbidity with depression. The use of benzodiazepines or sedative medications was not correlated with caffeine intake. CONCLUSION: High caffeine consumption in PD patients could be explained by the development of tolerance with regular use of this substance. Subtypes of sensitive and non-sensitive PD patients could also explain why some of these patients are able to tolerate high doses of caffeine.
format Online
Article
Text
id pubmed-6882139
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-68821392019-12-09 Panic Disorder and Chronic Caffeine Use: A Case-control Study Santos, Veruska Andrea Hoirisch-Clapauch, Silvia Nardi, Antonio E. Freire, Rafael Christophe Clin Pract Epidemiol Ment Health Clinical Practice Epidemiology in Mental Health BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemographic or clinical features. METHODS: 65 adults with PD and 66 healthy controls were included in the current study. Their caffeine intake within the previous week was quantified with a questionnaire and compared. Harmful caffeine use was defined as consumption above 400 mg/day of caffeine. We tested for correlations between caffeine intake, demographic and clinical features. RESULTS: Patients consumed significantly more caffeine than controls (P < 0.001). 14% (N = 9) of the PD patients made harmful use of caffeine. The use of caffeine-containing medications was observed in 40% (N = 26) of the PD patients and 6% (N = 4) of controls. Consumption of energy drinks was observed in 11% (N = 7) of PD patients and in none of the healthy subjects. Patients reported sleeping significantly less than controls (P < 0.001). In PD patients, caffeine consumption was not correlated with the presence of panic attacks or comorbidity with depression. The use of benzodiazepines or sedative medications was not correlated with caffeine intake. CONCLUSION: High caffeine consumption in PD patients could be explained by the development of tolerance with regular use of this substance. Subtypes of sensitive and non-sensitive PD patients could also explain why some of these patients are able to tolerate high doses of caffeine. Bentham Science Publishers 2019-09-30 /pmc/articles/PMC6882139/ /pubmed/31819760 http://dx.doi.org/10.2174/1745017901915010120 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Clinical Practice Epidemiology in Mental Health
Santos, Veruska Andrea
Hoirisch-Clapauch, Silvia
Nardi, Antonio E.
Freire, Rafael Christophe
Panic Disorder and Chronic Caffeine Use: A Case-control Study
title Panic Disorder and Chronic Caffeine Use: A Case-control Study
title_full Panic Disorder and Chronic Caffeine Use: A Case-control Study
title_fullStr Panic Disorder and Chronic Caffeine Use: A Case-control Study
title_full_unstemmed Panic Disorder and Chronic Caffeine Use: A Case-control Study
title_short Panic Disorder and Chronic Caffeine Use: A Case-control Study
title_sort panic disorder and chronic caffeine use: a case-control study
topic Clinical Practice Epidemiology in Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882139/
https://www.ncbi.nlm.nih.gov/pubmed/31819760
http://dx.doi.org/10.2174/1745017901915010120
work_keys_str_mv AT santosveruskaandrea panicdisorderandchroniccaffeineuseacasecontrolstudy
AT hoirischclapauchsilvia panicdisorderandchroniccaffeineuseacasecontrolstudy
AT nardiantonioe panicdisorderandchroniccaffeineuseacasecontrolstudy
AT freirerafaelchristophe panicdisorderandchroniccaffeineuseacasecontrolstudy